Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: HIV, FARMACOCINÉTICA, TUBERCULOSE, ESTUDOS PROSPECTIVOS
ABNT
NARDOTTO, Glauco Henrique Balthazar; BOLLELA, Valdes Roberto; ROCHA, Adriana; DELLA PASQUA, Oscar; LANCHOTE, Vera Lucia. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, Malden, 2022. Disponível em: < https://doi.org/10.1111/cts.13169 > DOI: 10.1111/cts.13169.APA
Nardotto, G. H. B., Bollela, V. R., Rocha, A., Della Pasqua, O., & Lanchote, V. L. (2022). No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science. doi:10.1111/cts.13169NLM
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ;Available from: https://doi.org/10.1111/cts.13169Vancouver
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ;Available from: https://doi.org/10.1111/cts.13169